The average one-year price target for Enveric Biosciences (NasdaqCM:ENVB) has been revised to $122.40 / share. This is an increase of 1,100.00% from the prior estimate of $10.20 dated September 27, ...

Enveric Biosciences secures five new U.S. patents, enhancing its neuropsychiatric EVM301 portfolio with innovative tryptamine derivatives. Lead candidate EB-003 targets depression and anxiety, aiming ...

Enveric Biosciences, Inc. ENVB has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 series of molecules being ...

The most recent trading session ended with Enveric Biosciences, Inc. (ENVB) standing at $0.90, reflecting a -0.56% shift from the previouse trading day's closing. The stock trailed the S&P 500, which ...

Detailed price information for Enveric Biosciences Inc (ENVB-Q) from The Globe and Mail including charting and trades.

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Enveric Biosciences (NASDAQ: ENVB) stock was up 136% yesterday on the back of a patent decision. “...the company said it will get a U.S. patent decisionpatent related to its psilocin prodrug EB-373 ...

In a challenging economic climate, ENVB stock has reached a new 52-week low, dipping to $0.4. This significant downturn reflects broader market trends and investor sentiment. Over the past year, the ...